Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cevimeline Ophthalmic Solution in Dry Eye Disease
NCT06543303Phase 2Completed
- Sponsor
- BioTheraVision
- Start
- Dec 2024
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of BTV100 in dry eye disease (DED), sponsored by BioTheraVision. Started Dec 2024; status: completed.
02
Drugs
BTV100
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT06543303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06543303.